Penetration of HIV-1 protease inhibitors into CSF and semen

HIV Medicine

Volumn 1, Issue SUPPL. 2, 2000, Pages 18-22

  Taylor, S ^a,c   Pereira, A ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002290916     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2000.00002.x     Document Type: Article

References (27)

1. Taylor S, Back DJ, Van Heeswijk R et al. Antiviral drug concentrations in semen of HFV-infected men are drug-specific. Antiviral Ther 2000; 5: abstract 14.
2. Enting RH, Hoetelmans RM, Lange JMA, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998; 12: 1941-1955.
3. Molla A, Vasavandonda S, Kumar G, eraJ. Human serum attenuates the activity of protease inhibitors towards wild-type and mutant human immunodeficiency virus. Virology 1998; 25: 255-262.
4. Zhang X, Schooly R, Gerber J, eraJ. The effect of increasing ctracid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180: 1933-1937.
5. Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA. Resistance to HIV-1 protease inhibitors and predicted responses to therapy. Antiviral Ther 2000; 5: 2 (abstract).
6. Glynn SL, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiviral agents. J Pharm Sei 1998; 87: 306-310.
7. Lee CGL, Gottesman MM, Cardarelli CO, eraJ. HIV-1 protease inhibitors are substrates for the MDRl multidrug transporter. Biochemistry 1998; 37: 3594-3601.
8. Kirn RB, Fromm MF, Vandel C, Leake B, Wood AJJ, Roden DM. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin Invest 1998; 101: 289-294.
9. Polli JW, Jarrett JL, Studenberg SD, etal. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharma Res 1999; 16: 1206-1212.
10. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV-1 protease inhibitors. AIDS 2000; 14: 237-242.
11. Martin C, Sonnerborg A, Svensson JO, Stahle L. Indinavirbased treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS 1999; 13: 1227-1232.
12. Brinkman K, Kroon F, Hugen PW, Burger DM. Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1infected patients. AIDS 1998; 12: 537.
13. Taylor S, Back DJ, Drake SMD, etal. Antiretroviral drug concentrations in semen of HIV-1 infected men: differential penetration of indinavir, ritonavir and saquinavir. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000; abstract 318.
14. Van Praag R, Weverling G, Portegies P, etal. Enhanced penetration of indinavir in cerebrospinal fluid after addition of low dose ritonavir. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000; abstract 312.
15. Moyle GJ, Sadler M, Buss N. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy. Clin Infect Dis 1999; 28: 403-404.
16. Kravcik S, Gallicano K, Roth V, etal. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J AIDS 1999; 21: 371-375.
17. Gisolf EH, Jurriaans S, Hoetelmans R, etal. Ritonavir (RTV)/ Saquinavir (SQV) versus RTV/SQV/D4T in cerebrospinal fluid (CSF): drug concentrations and the effect of these regimens on CSF HIV-RNA levels. AIDS 1998; 12: S8 (abstract 403).
18. Taylor S, Back DJ, Workman J, etal. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 1999; 13: 859-860.
19. Winter A, Taylor S, Workman J, et al Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. SCJT Transm Infect 1999; 75: 261-263.
20. Aweeka F, Jayewardene A, Staprans S, étal. Failure to detect nelfmavir in the cerebrospinal fluid of HIV-1 - infected patients with and without AIDS dementia complex. J AIDS Hum Retrovirol 1999; 20: 39-43.
21. Hass D, Clough L, Johnson B, étal. Quantification of nelfmavir and its active metabolite (M8) in CSF and plasma and correlation with CSF HIV-1 RNA response. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000; abstract 313.
22. Reijers M, Van Heeswijk R, Jurrians S, eraJ. The concentrations of D4T, 3TC, nelfmavir and saquinavir in plasma, cerebrospinal fluid and semen. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000; abstract 316.
23. Murphy R, Currier J, Gerber J, eraJ. Antiviral activity and pharmacokinetics of amprenavir with our without zidovudine/ 3TC in the cerebrospinal fluid of HIV-infected adults. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000; abstract 314.
24. Pereira A, Eron JJ, Dunn J, eraJ. Analysis of amprenavir, 3TC/ AZT in blood and seminal plasma: penetration of amprenavir into the male genital tract. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000; abstract 317.
25. Groothuis DR, Levy RM. The entry of antiviral and antiretroviral drugs into the central nervous system. JNeurovirol 1997; 3: 387-400.
26. Kashuba ADM, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43: 1817-1826.
27. Gallicano K. Antiretroviral drug concentrations in semen. Antimicrob Agents Chemother 2000; 44.